摘要
目的研究单次500 mg利妥昔单抗治疗糖皮质激素无效或复发的成人原发免疫性血小板减少症的临床疗效及安全性。方法收集2015年1月至12月就诊于山东大学齐鲁医院血液内科,确诊为原发免疫性血小板减少症经糖皮质激素治疗疗效不佳或复发的患者资料30例,利妥昔单抗500 mg单次给药,观察其临床疗效、起效时间、药效维持时间及不良反应。结果 30例患者治疗后完全缓解13例(43.33%),有效9例(30.00%),无效8例(26.67%)。完全缓解及有效的患者(n=22)中,中位起效时间为30 d(7~60 d),15例(68.18%)疗效维持时间超过1年,疗效维持时间最短者为3个月;未出现严重不良反应。结论单次500 mg利妥昔单抗治疗原发免疫性血小板减少症安全、有效,且能减少患者住院时间及次数,可用于经激素治疗无效或复发的原发免疫性血小板减少症的治疗。
Objective To investigate the activity,safety and response duration of single dose rituximab（RTX） in previously treated primary immune thrombocytopenia（ITP）. Methods Thirty patients with ITP who had failed to respond to glucocorticosteroids were treated with a single dosage of 500 mg rituximab in Department of Hematology,Qilu Hospital of Shandong University. The clinical effect,onset time,duration of efficacy and adverse reactions were observed.Results Response and complete response were achieved in 9（30.00%） and 13（43.33%） patients,respectively. In responders,the median time to response was 30 days（range： 7-60 d）. Sustained response was maintained for over 12 months in 68.18%（15/22） patients with the shortest sustained response time of 3 months. No serious infectious,hematologic or extra-hematologic complications were documented during follow-up. Conclusion The single dose of 500 mg rituximab may be effective and safe for corticosteroid-resistant or relapsed patients with ITP.
作者
聂牧
倪晓菲
秦平
杨丹丹
李强
侯明
彭军
张晓琳
石艳
NIE Mu, NI Xiaofei, QIN Ping, YANG Dandan, LI Qiang, HOU Ming, PENG Jun, ZHANG Xiaolin, SHI Yan(Department of Hematology, Qilu Hospital of Shandong University, Jinan 250012, Shandong, Chin)
出处
《山东大学学报（医学版）》
CAS
北大核心
2018年第5期81-84,共4页
Journal of Shandong University:Health Sciences
基金
国家自然科学基金(81170475
81470285)
